
    
      All participants will receive three primary doses of their assigned study the vaccine, on
      Days 0, 60, and 120. They will be assessed for immunogenicity on Day 0 before vaccination and
      Day 150 post-vaccination. Safety will be assessed for all participants throughout the study,
      up to Day 157.
    
  